Would you like to help shape the future of biological research? The NSF Directorate for Biological Sciences (BIO) recently published a Dear Colleague Letter (DCL) seeking high-level ideas from the community on the research questions and topics that would benefit from NSF investment in a truly integrated research environment.
As a reminder, this is a call for ideas, not proposals, meaning there is no funding associated with this DCL, but rather provides the community with an opportunity to share its visions for the future of biology. Any ideas you have – even those that include collaborations with fields outside the biological sciences – will be considered and will help inform BIO strategies for supporting a number of Integration Institutes over the next several years.
The deadline for submissions is March 1. Please see the Dear Colleague Letter (NSF 19-027) for details on how to submit your ideas, and direct any questions to BIO-RFI-II@nsf.gov.
The NSF Directorate for Biological Sciences has published a Dear Colleague Letter seeking ideas from the community on Integration Institutes for cross-cutting biology. These institutes would support collaborative teams of researchers to address questions that span multiple levels of organization in living systems and require expertise from diverse biological subdisciplines.
This is not a call for research proposals, but rather for high-level ideas about the types of questions and resources that would benefit from NSF investment in a truly integrated research environment.
The deadline for submissions is March 1. Please see the Dear Colleague Letter (NSF 19-027) for details on how to submit your ideas.
In August, the BIO directorate released new solicitations to its proposal submission process to eliminate deadlines and limit the number of proposals that could be submitted to a given division annually by a PI or co-PI. As BIO was receiving far more worthy proposals than it has money to support, this submission cap was established with a view to ensuring that BIO’s merit review process would not be overwhelmed with the move to no deadlines.
In the ensuing three months, the community expressed serious concern that this new policy would hinder collaboration as well as limit funding prospects for new investigators. BIO places a high value on collaboration and on fostering careers of new investigators; thus, we held internal discussions to consider ways to address these concerns. In addition, relatively few proposals have been submitted to BIO since the release of the solicitations.
Having listened to community concern and tracked the current low rate of submission, and following extensive internal consultation, BIO is lifting all PI or co-PI restrictions on proposal submission for FY 2019, effective immediately.
BIO recognizes that it is important to track the effects of the no-deadline policy on proposal submission patterns, to ensure that a high-quality review process is sustained. Therefore, we are seeking approval from the Biological Sciences Advisory Committee to establish a subcommittee to assist in developing the evidence base for any future policy changes that may be needed.
Solicitations for proposals will be amended and released over the next few weeks to reflect these changes.
Joanne Tornow, PhD
Acting Assistant Director for the Biological Sciences
The BIO advisory committee will hold a special meeting on Friday, November 16th from 2:30-4:30 PM to discuss immediately establishing a subcommittee to consider different options for addressing community concerns with the BIO proposal submission limits.
This meeting will be held via teleconference among the Advisory Committee members. Public visitors will be able to attend the meeting in person at NSF headquarters; please contact Alexis Patullo at email@example.com to request a visitor badge.
Accelerating Research through International Network-to-Network Collaborations (AccelNet) supports strategic linkages among U.S. research networks and complementary networks abroad that will leverage research and educational resources to tackle grand scientific challenges that require significant coordinated international efforts. AccelNet invites proposals, submitted by U.S.-based researchers, for the creation of international networks of networks in research areas aligned either with one of the NSF Big Ideas or a community-identified challenge with international dimensions.
For the first competition, Letters of Intent for are due December 21, 2018 and Full Proposals due February 28, 2019. The NSF Office of International Science and Engineering (OISE) funded several workshops that will take place in 2019, and we will offer webinars for the community.
The first webinar will be this Monday, November 5 – visit the event page for webcast info. Updates on future webinars will be posted on the program page.
The National Science Foundation (NSF) has taken the next steps in its agency-wide effort to protect the research community from harassment, publishing a term and condition that requires awardee organizations to report findings and determinations of sexual harassment, as well as establishing a secure online portal for submitting harassment notifications.
BIO recently welcomed a new Acting Assistant Director, Dr. Joanne Tornow. Though she is coming to BIO after six years in NSF’s Directorate for Social, Behavioral and Economic Sciences and the Office of Information and Resource Management, Dr. Tornow is no stranger BIO, having spent more than a decade in a variety of roles across the Directorate. We sat down with Dr. Tornow to get to know her a little better and welcome her back to her first home at NSF.
When did your interest in the sciences first begin?
I trace back my falling in love with biology and genetics to my 9th grade biology class. It all just made perfect sense and I loved it, so from then on, I was a biology person. At the time that I was in college, molecular biology did not really exist as a discipline, but microbial biology and microbial and molecular genetics was just starting, so I concentrated on what was then a very emerging area of microbial genetics. As I progressed, there was really very little debate in my own mind about what I was interested in. I love biology and knew I wanted to pursue it as a career.
Can you tell us a little bit about your journey from a career as a traditional, academic researcher to science administrator?
I did the traditional academic path – graduate school, postdoc, faculty position – and then there was an opportunity during my sabbatical to do something completely different that I was really interested in.
At the time, Dolly had just been cloned the year before and we were in the middle of the Human Genome Project. I was teaching genetics to undergraduates and molecular genetics graduate students, and these events were raising all of these questions about the intersection of science and policy, genetic privacy, cloning – it was really a fascinating time. So when I stumbled on the AAAS policy fellowship, I thought it would be a great opportunity to go and see how the policy side intersected with the science and then bring that back to the classroom.
I spent a year working on the Senate Veterans’ Affairs committee, getting experience working on the Hill and understanding how that process worked – how the federal budget is generated and how it drives policy. Then an opportunity came up to go to OSTP [the White House Office of Science and Technology Policy] for a year, and there I was able to work on things that were a little bit more relevant to my science.
What was your favorite part of working on the policy side of things?
Just a month or two after I started my fellowship in OSTP, the first papers on isolating human embryonic stem cells came out. Every month or so, something else was getting cloned. It created some really great policy questions, and so it was a wonderful time for me to be at OSTP – that was a fabulous year.
How did you ending up coming to NSF?
At the end of that year, I was getting ready to go back to my institution. I had been in contact with NSF because I knew that when I had initially planned to come to DC on my sabbatical that NSF had been an option. A position was available as a rotator and they reached out to me. By that time, after two years in DC I had sort of made the switch in my mind from doing the academic life to thinking about science in the bigger context, and it was really appealing to me both personally and professionally to stay in this area, so I took the position.
You and BIO have a long history together! When were you last here, and what projects were you involved with?
Starting in the Fall of 1999, I was program director for gene expression in the division of Molecular and Cellular Biosciences (MCB). The portfolio for gene expression was much broader than understanding the control of transcription, which was my area of expertise. I was a program director in MCB for about six and a half years before leaving for a little bit to do a detail in the Directorate for Education and Human Resources (EHR) front office.
After that, I came back to be senior advisor in the BIO front office, but as it turned out, I went up to the Director’s office for about 8 months on a detail to work on a particular project for the Deputy Director, and so spent very little time in the front office. After that, I returned to BIO and was the Acting Division Director for MCB for two years.
By that time [former BIO AD] Jim Collins was finishing up his tenure and left, and I moved in to be the acting Executive Officer [equivalent to the current Deputy Assistant Director]. When a new AD was found two years later, there were a variety of vacancies in the Deputy AD spots, so I applied for those and that’s when I moved to the Directorate for Social, Behavior and Economic Sciences (SBE) as Deputy AD.
Each of these jobs – that whole path, including my details in EHR and in the OD, and my time in OIRM – all gave me different perspectives and really helped me when I came back to be an Acting Division Director and now Acting Assistant Director in BIO. Having spent the time at OSTP, on the Hill, in the OD – all of those experiences helped me be more effective here at NSF.
What are you most looking forward to for your time as Acting Assistant Director for BIO?
There are a couple of things that I’m really looking forward to. One is that it’s been six years since I’ve been in BIO and I’m just really loving getting back in touch with BIO and catching up on all that’s happened – all the ways that the science and the programs in BIO have advanced. So that’s probably the best part about this – I’m really just getting back to my first love.
On January 10, 2018, Dr. Jim Olds’ term as Assistant Director for Biological Sciences came to an end. Since taking up the post in September 2014, Dr. Olds has led BIO through many big changes, including the conception of the Rules of Life Big Idea and implementation of a no-deadline submission mechanism for receiving and reviewing proposals. All of us at BIO would like to thank Dr. Olds for his excellent leadership over the past three and a half years, and wish him the best as he returns to George Mason University.
Dr. Joanne Tornow, Head of the Office of Information and Resource Management (OIRM) and former BIO Acting Deputy Assistant Director, will be taking up the mantle as Acting Assistant Director for BIO while the search for Dr. Olds’ successor is underway. Stay tuned to learn more about Dr. Tornow and the exciting things she has planned for the directorate in the coming months!
Due to revolutionary new technologies, neuroscientists are poised to significantly advance our understanding of the brain and behavior, with profound implications for health and society.
To enhance collaboration and better coordinate global efforts in fundamental neuroscience research, the National Science Foundation (NSF) will support a conference of scientists and government representatives from countries with significant investments in neuroscience research. Attendees, many of whom are members of the U.S. BRAIN Initiative, a public-private collaborative effort aimed at accelerating the development and application of new technologies to revolutionize our understanding of the brain, will exchange ideas and information about their efforts and identify new opportunities for collaboration.
“Brain diseases and disorders affect millions of families worldwide, leading to billions of dollars in medical expenses and lost productivity,” said NSF Director France Córdova, who will deliver opening remarks at the event. “This event is intended to promote collaboration and cooperation in emerging, large-scale international brain projects to further advance neuroscience research. NSF plays a pivotal role in funding brain research, bringing the research community together and shaping the vision for a global brain initiative.”
The NSF’s Assistant Director for Biological Sciences, Dr. Jim Olds, will present information about the NSF’s participation in the U.S. BRAIN Initiative.
On June 29, 2016, the Cancer Moonshot Summit was held on the campus of Howard University in Washington, DC. The National Science Foundation’s Assistant Director for the Directorate for Biological Sciences, Dr. Jim Olds, was pleased to represent the Foundation at the event.
From the Office of the Vice President of the United States:
“In his final State of the Union address, the President tasked the Vice President with heading up a new national effort, the Cancer Moonshot. The ultimate goal is to double the rate of progress—to make a decade’s worth of advances in cancer prevention, diagnosis, treatment and care in five years—to ultimately end cancer as we know it.
The goals of this effort cannot be achieved by one person, one organization, or one discipline. Solving the complexities of cancer will require the formation of new alliances to defy the bounds of innovation and accelerate the prevention, diagnosis, treatment, and—ultimately—a cure. It’s going to require millions of Americans speaking up and contributing what they’re able.
The Cancer Moonshot Summit will be a venue to bring together all sectors that have a role to play in making progress on the Cancer Moonshot goals to share new ideas and launch new collaborations and actions.
The Cancer Moonshot is a mission, and all of us #CanServe. How will you make a difference, break down barriers to progress, or catalyze change where you live or work?”